Rottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.
Spain’s biotech association Asebio announced new record numbers from its biotech investor day held as part of the European Biotech Week.
Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.
Entasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the WHO priority pathogen N. gonorrhoea.
BASF SE has strengthened its capabilities in recombinant production of natural ingredients by acquiring Dutch Isobionics BV and collaborating with Conagen Inc.
290 participants from 18 nations at the late summer edition of the European Chemistry Partnering in Düsseldorf
- High level or participation from Southern and Eastern Europe
- Attendance record and more than 500 arranged networking meetings
- 4th European Chemistry Partnering will take place on 27 February 2020 in Frankfurt
- Podcast of the panel discussion Digitization Networking in Chemistry available soon
An antimicrobial molecule produced by the human microbiota gut may help fight drug-resistant infections.
German Tacalyx GmbH has baged €7m in seed financing to generate antibodies that home in on tumour-antigene specific carbohydrates (TACAs) of glycans.
Evotec SE and Takeda Pharmaceutical Company Ltd have entered a strategic drug discovery collaboration potentially worth $850m.
Under the agreement, Evotec will develop at least five small molecule discovery programmes against targets identified by Takeda in oncology, gastroenterology, neuroscience and rare diseases. Takeda will have the option to assume responsibility at lead series and upon Evotec delivering a pre-clinical candidate.
Under the terms of the collaboration, Takeda will pay Evotec an undiclosed upfront fee to get access to its platforms. Additionally, Evotec is eligible to receive pre-clinical, clinical, and commercial milestones that can total in excess of $170 m per programme as well as tiered royalties on future sales.
At its September meeting, the EMAs CHMP recommended three innovative medicines for EU market approval.